Recently, EGFR targeting PEGylated liposomes containing doxorubicin were shown to be able to hone to tumor tissue in nine glioblastoma patients, but only in areas where the BBB was disrupted in a Phase I trial.(Kasenda et al., 2022) Adding glutathione (GSH) to PEGylated liposomes utilizes naturally present GSH-transporters to cross the BBB and showed excellent tumor response in mice.(Gaillard et al., 2014) A Phase I/IIA trial showed good safety(Brandsma et al., 2014) and further studies are currently being done in patients with breast cancer brain metastases (NCT01818713). The gene discussed is EGFR; the disease is neoplasm.